GAGEOMACROLACTIN 3


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HUEUKSNRFPKEMR-VSIUFNMPSA-N
Smiles	C[C@@H]1CCCCC\C=C\[C@H](O)C[C@@H](O)C\C=C/C=C/[C@H](C\C=C\C=C/C(=O)O1)O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O
InChI	InChI=1S/C30H46O10/c1-21-13-7-3-2-4-8-14-22(32)19-23(33)15-9-5-10-16-24(17-11-6-12-18-26(34)38-21)39-30-29(37)28(36)27(35)25(20-31)40-30/h5-6,8-12,14,16,18,21-25,27-33,35-37H,2-4,7,13,15,17,19-20H2,1H3/b9-5-,11-6+,14-8+,16-10+,18-12-/t21-,22+,23+,24-,25+,27+,28-,29+,30+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C30H46O10
Molecular Weight	566.68
AlogP	2.21
Hydrogen Bond Acceptor	10.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	3.0
Polar Surface Area	166.14
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	40.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Homo sapiens (human) NUGC3 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) PC3 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) NCI-H23 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) HCT15 cell	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) ACHN cells	Homo sapiens	30.0 ug.mL-1
Antifungal activity against Candida albicans assessed as inhibition of mycelial growth	Candida albicans	None
Antifungal activity against Aspergillus niger assessed as inhibition of mycelial growth	Aspergillus niger	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2289501
PubChem	76334759

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).